Argenx Se (ARGX) Income from Discontinued Operations (2018 - 2025)

Argenx Se's (ARGX) quarterly Income from Discontinued Operations came in at 129656000.0 in Q4 2025, down 81.15% YoY from 687652000.0 in Q4 2024, and up 210.22% on a QoQ basis from 41795000.0 in Q3 2025.

Argenx Se (ARGX) Income from Discontinued Operations (2018 - 2025) Analysis & Trends

Argenx Se (ARGX) has 6 years of Income from Discontinued Operations data on file, last reported at 129656000.0 in Q4 2025.

  • Quarterly Income from Discontinued Operations fell 81.15% year-over-year to 129656000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 97018000.0 (down 87.03% YoY) and the FY2025 annual result came in at 13428000.0, down 98.2% from the prior year.
  • Income from Discontinued Operations climbed to 129656000.0 in Q4 2025, from 41795000.0 in the prior quarter.
  • In the past five years, Income from Discontinued Operations ranged from a high of 687652000.0 in Q4 2024 to a low of 41541000.0 in Q2 2025.
  • A 5-year average of 49102944.44 and a median of 6522000.0 in 2021 frame the typical range for Income from Discontinued Operations.
  • Annual changes were most pronounced in 2023 — Income from Discontinued Operations slumped 1547.39% — and 2024, when it jumped 1909.9%.
  • Tracing ARGX's Income from Discontinued Operations over 5 years: stood at 7062000.0 in 2021, then tumbled by 62.83% to 2625000.0 in 2022, then tumbled by 1547.39% to 37994000.0 in 2023, then jumped by 1909.9% to 687652000.0 in 2024, then sank by 81.15% to 129656000.0 in 2025.
  • The last three Income from Discontinued Operations figures came in at 129656000.0 (Q4 2025), 41795000.0 (Q3 2025), and 41541000.0 (Q2 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Discontinued) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Roivant Sciences 26.16 Bn 26.85 Bn 1.16 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 129.66 Mn
Sep 30, 2025 41.80 Mn
Jun 30, 2025 -41.54 Mn
Mar 31, 2025 -32.89 Mn
Dec 31, 2024 687.65 Mn
Sep 30, 2024 3.39 Mn
Jun 30, 2024 44.07 Mn
Mar 31, 2024 12.75 Mn
Dec 31, 2023 -37.99 Mn
Sep 30, 2023 10.64 Mn
Jun 30, 2023 -10.51 Mn
Mar 31, 2023 47.31 Mn
Dec 31, 2022 2.63 Mn
Sep 30, 2022 5.98 Mn
Jun 30, 2022 8.23 Mn
Mar 31, 2022 2.89 Mn
Dec 31, 2021 7.06 Mn
Sep 30, 2021 2.75 Mn
Sep 30, 2018 1,163.13